Graphex Group ADR ( (GRFXY)) just unveiled an announcement. On November 11, 2025, Graphex Group Limited announced an equipment purchase agreement for an intelligent carbon coating processing line, ...

Traditional OEE often masks micro-level inefficiencies that accumulate into major production losses. Micro OEE (mOEE) measures efficiency at the smallest production steps, enabling precise ...

An announcement from Graphex Group Limited ( (HK:6128)) is now available. Graphex Group Limited has announced a discloseable transaction involving the purchase of an intelligent carbon coating ...

Since the NBA went to its current lottery format in 1986, these 18 players were picked No. 1 overall and won ROY, too. From NBA.com Staff Victor Wembanyama was the unanimous winner of the 2023-24 Kia ...

In the Southern Hemisphere, the adjusted flu vaccine effectiveness rates against outpatient visits and hospitalizations were 50.4% and 49.7%. Only 21.3% of flu outpatients and 15.9% of hospitalized ...

C.J. Stroud wasn't the only problem in the Houston Texans' 14-9 loss on Sunday to the Los Angeles Rams, but one chart certainly is painting him as part of the problem in the overall outing for the ...

CEO Sam Altman called a strange graph in its GPT-5 presentation a ‘mega chart screwup.’ CEO Sam Altman called a strange graph in its GPT-5 presentation a ‘mega chart screwup.’ is a senior reporter ...

New York, United States, July 30, 2025 (GLOBE NEWSWIRE) -- Graphjet Technology (“Graphjet” or “the Company”) is pleased to announce the successful arrival of its new machineries and equipment to its ...

Manufacturing facilities are facing challenges in maintaining efficiency while meeting increasing production demands. Allie AI — an artificial intelligence company — is working to redesign the ...

Bengals WR Ja'Marr Chase will be the first overall pick in countless fantasy football drafts this season. / Katie Stratman-Imagn Images Well, it’s finally here. The moment you’ve been waiting all ...

Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non–small-cell lung cancer (NSCLC) in a phase 3 trial.